ArticleFrontiers in pharmacology2023

Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N.

Na Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.